Results 141 to 150 of about 24,434,811 (177)

Synthesis of 3-(arylamino) quinazoline-2,4(1H,3H)-dione derivatives via TBHP/I2: Molecular docking, MD simulation, DFT, and pharmacological evaluation as MTH1 inhibitors. [PDF]

PLoS One
Karim MG, Mehrdad M, Gheidari D, Gheidari NZ.   +3 more
europepmc   +1 more source

Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor. [PDF]

J Med Chem
Papillon JPN, Yuan J, Hesse MJ, Zhang L, Robinson RI, Ware NF, Hornak V, Karki RG, Kirrane T, Garland K, Joseph S, Moquin SA, Lakshminarayana SB, Tandeske L, Dovala D, Knapp M, Ornelas E, Fuller D, Ho PI, Xie X, Vulic K, Skolnik SM, Gao J, Zambrowski M, Spiess M, Duca JS, Busby SA, Schirle M, Robinson M, Shi PY, Moser HE, Sarko C, Bradner JE, Diagana TT, Tallarico JA.   +34 more
europepmc   +1 more source

Discovery of cytotoxic indolo[1,2-<i>c</i>]quinazoline derivatives through scaffold-based design. [PDF]

Beilstein J Org Chem
Khabarov DV, Litvinova VA, Dezhenkova LG, Kaluzhny DN, Tikhomirov AS, Shchekotikhin AE.   +5 more
europepmc   +1 more source

Anti-Inflammatory Evaluation of Pyrazino[2,1-<i>b</i>]quinazoline-3,6-dione Derivatives Inspired by Fiscalin B. [PDF]

Pharmaceuticals (Basel)
Martins MS, Pinto MMM, Almeida IF, Cruz MT, Sousa E.   +4 more
europepmc   +1 more source

Recent advances in HER2-targeted inhibitors for cancer therapy. [PDF]

Pharm Sci Adv
Zhu W, Lu X.
europepmc   +1 more source

Molecular Dynamics-Based validation of a quinazoline-based KRAS inhibitor (C9) identified through QSAR-guided discovery. [PDF]

Front Bioinform
Osasan SA, George OA, Daramola O, Adefolalu OA, Hind AA, Jawaher MA, Ibrahim WO, Ajetunmobi OI.   +7 more
europepmc   +1 more source

Synthesis of 3-(Quinazolin-4-yl)propionic Acids via an Acid-Catalyzed Rearrangement of 4-Oxobutyronitriles. [PDF]

Int J Mol Sci
Aksenov NA, Kurlikov AE, Barbolin AP, Karaseva PS, Baziyants MM, Glotova EA, Kurenkov IA, Aksenov DA, Aksenov AV.   +8 more
europepmc   +1 more source

Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer. [PDF]

RSC Adv
Elwaie TA, Aref MMA, Ali HI.
europepmc   +1 more source

Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities. [PDF]

Molecules
Xin Y, Wu Q, Gao Y, Xiao C, You Q, Jiang Z, Lu M.   +6 more
europepmc   +1 more source

Development of substituted 2-(4-(sulfonyl)piperazin-1-yl)quinazoline molecular hybrids as a new class of antimalarials. [PDF]

RSC Adv
Madhav H, Panda A, Datta D, Shaheen K, Rahman A, Khan AT, Bhattacharjee S, Kumar D, Malhotra P, Hoda N.   +9 more
europepmc   +1 more source